Reminder: The pictures displayed on this site maybe different from the actual appearance of the product,their maybe a delay in updating the recent picture if their a newly launched packaging from the manufacturer
PHOCAPMA is a particular small molecule MET inhibitor. Tabrecta (capmatinib) was approved by the US Food and Drug Administration in May 2020 for the treatment of patients with non-small cell lung cancer who have localised or metastatic MET exon 14 skippings (METEX 14) mutations (NSCLC). It's the fir
Pharma 2 Vientiane
Please negotiate the logistics method with customer service, customer service Whatsapp/Wechat
Please follow the doctor’s advice when taking medicines. The mall only guarantees the quality of the medicines and does not provide medical advice.
PHOCAPMA is a receptor tyrosine kinase that activates signaling pathways involved in organ regeneration and tissue repair. Due to aberrant c-Met activation, which can be caused by mutations, amplification, or overexpression, multiple downstream signaling pathways, including STAT3, PI3K/ATK, and RAS/MAPK, are overactivated. Non-small cell lung cancer (NSCLC) has been linked to mutations in the MET gene, with a rate of MET amplification ranging from 1.4 percent to 21% in EGFR-TKI-naive patients with NSCLC. Because of this, c-Met has become a desirable target in the therapy of NSCLC.